How Brainomix Is Bringing AI Into Stroke and Lung Care

In this episode of The Open Loop, Chay Carter is joined by Dr George Harston, Chief Medical and Innovation Officer at Brainomix. George shares how Brainomix is building clinical AI software to support treatment decisions in stroke and fibrosing lung disease, helping clinicians extract meaningful information from medical scans and use it in time-critical patient pathways. This is a practical conversation about what it takes to move healthcare AI from algorithm performance into real clinical adoption. We explore why AI is only valuable when it integrates into workflows, supports clinician decision-making, and improves patient outcomes. We also discuss Brainomix’s journey from Oxford spinout to NHS adoption, Series C growth, and US expansion, as well as the company’s work with hospitals, pharma partners, and clinical trials. Key takeaways: 🔹 Why stroke care depends on faster identification and treatment decisions🔹 Why clinical AI needs workflow integration, not just strong algorithms🔹 How Brainomix is applying imaging AI across stroke and fibrosing lung disease🔹 What it takes to drive adoption across hospitals, healthcare systems, and the US market🔹 Why the future of healthcare AI will depend on evidence, implementation, and patient impact Host:Chay CarterFounder, Carter SciencesCo-Founder, Reccy NeuroLinkedIn: https://www.linkedin.com/in/chay-carter/ Guest:Dr. George HarstonChief Medical and Innovation Officer at BrainomixLinkedIn: https://www.linkedin.com/in/george-harston-3b9496b1/Key Chapters:00:00 Introduction to Brainomix and Dr George Harston04:01 From Stroke Medicine to Clinical AI06:54 Why AI Needs to Fit the Clinical Workflow12:30 How Imaging AI Can Improve Patient Outcomes18:25 Expanding AI Support into Fibrosing Lung Disease24:19 Navigating US Healthcare, Reimbursement, and Adoption30:09 The Future of Stroke Treatment and Clinical AI36:23 Brain Data, Personalised Medicine, and What Comes Next The Open Loop is a podcast exploring the people, companies, and ideas shaping the future of neurotechnology.